Drug Trial Radar · NCT01442727
Selenium in the Treatment of Arsenic Toxicity and Cancers
Last checked: Nov 20, 2026Latest source record: Oct 7, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
819
Actual
Start
Dec 2006
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- Texas Tech UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); American Cancer Society, Inc.
- First posted
- Sep 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Context: Approximately 100 million people throughout the world consume water contaminated with arsenic at levels above carcinogenic thresholds, including 40 million in Bangladesh alone, with up to one-fourth of deaths attributed to arsenic exposure in the worst-affected regions. There are no proven therapies for treating chronic arsenic toxicity or for preventing arsenical cancers. Selenium has been known to counter arsenic toxicity in a variety of animal models. The investigators have recently shown in animals and humans that this effect is mediated by the formation of \[(GS)2AsSe\]- , the seleno-bis(S-glutathionyl) arsinium ion, which is then rapidly excreted via the hepatobiliary system. Concurrently, two Phase II studies in China and Bangladesh have suggested clinical benefit to selenium supplementation in arsenicosis patients. Objective: To assess whether daily selenium supplementation counters arsenic toxicity in patients exposed to drinking water arsenic. If proven effective, selenium supplementation might be safely and cost-effectively implemented in the worst-affected localities.
Conditions
- Arsenical Melanosis
- Arsenical Keratosis
- Arsenical Cancers
- Arsenicosis
- Arsenic Exposure
- Arsenic Toxicity
- Arsenic Poisoning
Interventions
sodium seleniteDrug
200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
placeboDrug
dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
Primary outcomes
What the sponsor says the trial is designed to measure.
- changes in arsenical melanosisTime frame: 0 weeks (baseline), 24 weeks, and 48 weeks (end)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SETAC Trial Field Office
Kalibari Town, Chandpur District, Bangladesh
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.